Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab – a case report

Annals of Clinical and Translational Neurology

Volumn 3, Issue 11, 2016, Pages 889-892

  Mutzenbach, Johannes Sebastian ^a   Pikija, Slaven ^a   Otto, Ferdinand ^a   Halwachs, Ursula ^a   Weymayr, Friedrich ^a   Sellner, Johann ^a,b  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; DABIGATRAN ETEXILATE; HEPARIN; IDARUCIZUMAB; LOW DENSITY LIPOPROTEIN; SIMVASTATIN; TISSUE PLASMINOGEN ACTIVATOR;

AGED; ANTICOAGULATION; ARTICLE; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; CARDIOEMBOLIC STROKE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; DIZZINESS; DRUG DOSE INCREASE; HEADACHE; HOMONYMOUS HEMIANOPIA; HUMAN; KIDNEY FAILURE; LOW DRUG DOSE; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROLOGIC EXAMINATION; PAROXYSMAL ATRIAL FIBRILLATION; PRIORITY JOURNAL; PROGRESSIVE NONFLUENT APHASIA; TRANSTHORACIC ECHOCARDIOGRAPHY; VISUAL DISORDER;

EID: 85014481275     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.346     Document Type: Article

References (16)

1. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England J Med 2009;361:1139–1151.
2. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342–2352.
3. Goldhaber SZ, Schellong S, Kakkar A, et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thromb Haemost 2016;116: [Epub ahead of print].
4. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178–2185.
5. Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. New England J Med 2015;373:511–520.
6. Shahjouei S, Tsivgoulis G, Bavarsad Shahripour R, et al. Safety of intravenous thrombolysis among stroke patients taking new oral anticoagulants–case series and systematic review of reported cases. J Stroke Cerebrovasc Dis 2015;24:2685–2693.
7. Bladin C, Curnow J, Levi C, et al. Thrombolysis for acute ischaemic stroke in patients treated with dabigatran: practical guidance. In: Australasia SSo, editor. Victoria, Australia: Stroke Society of Australasia & The Australasian Society of Thrombosis and Haemostasis, New South Wales. 2014.
8. Diener HC, Foerch C, Riess H, et al. Treatment of acute ischaemic stroke with thrombolysis or thrombectomy in patients receiving anti-thrombotic treatment. Lancet Neurol 2013;12:677–688.
9. Hankey GJ, Norrving B, Hacke W, Steiner T. Management of acute stroke in patients taking novel oral anticoagulants. Int J Stroke 2014;9:627–632.
10. Kate M, Szkotak A, Witt A, et al. Proposed approach to thrombolysis in dabigatran-treated patients presenting with ischemic stroke. J Stroke Cerebrovasc Dis 2014;23:1351–1355.
11. Rybinnik I, Mullen MT, Messe S, et al. Treatment of acute stroke in patients on dabigatran: a survey of US stroke specialists. J Stroke Cerebrovasc Dis 2013;22:1312–1316.
12. Tummala R, Kavtaradze A, Gupta A, Ghosh RK. Specific antidotes against direct oral anticoagulants: a comprehensive review of clinical trials data. Int J Cardiol 2016;1:292–298.
13. Pfeilschifter W, Abruscato M, Hovelmann S, Baas H. Thrombolysis in a stroke patient on dabigatran anticoagulation: case report and synopsis of published cases. Case Rep Neurol 2013;5:56–61.
14. Heidbuchel H, Verhamme P, Alings M, et al. Updated European heart rhythm association practical guide on the use of non-vitamin-k antagonist anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2016; [Epub ahead of print].
15. Berrouschot J, Stoll A, Hogh T, Eschenfelder CC. Intravenous thrombolysis with recombinant tissue-type plasminogen activator in a stroke patient receiving dabigatran anticoagulant after antagonization with idarucizumab. Stroke 2016;47:1936–1938.
16. Schäfer N, Müller A, Wüllner U. Systemic thrombolysis for ischemic stroke after antagonizing dabigatran with idarucizumab-a case report. J Stroke Cerebrovasc Dis 2016;25(8):e126–7.